冠心病患者血清前蛋白转化酶枯草溶菌素9与小而密低密度脂蛋白胆固醇的相关性研究  

Study on the correlation between serum proprotein convertase subtilisin/kexin type 9 and small and dense low density lipoprotein cholesterol in patients with coronary artery disease

作　　者：韩耀霞[1] 张强[1] 边云飞[2] 张娜娜[1] 梁斌[2] 白瑞[2] 肖传实[1] HAN Yao-Xia ZHANG Qiang BIAN Yun-Fei ZHANG Na-Na LIANG Bin BAI Rui XIAO Chuan-Shi(Department of Cardiology, First Affiliated Hospital Department of Cardiology, Second Affiliated Hospital ＆ Clinical Cardiovascular Pharmacology Laboratory of Shanxi Province, Shanxi Medical University, Taiyuan, Shanxi 030001, China)

机构地区：[1]山西医科大学第一临床医学院心内科,山西省太原市030001 [2]山西医科大学第二临床医学院心内科山西省临床心血管药理实验室,山西省太原市030001

出　　处：《中国动脉硬化杂志》2017年第4期383-386,共4页Chinese Journal of Arteriosclerosis

摘　　要：目的探讨冠心病患者血清前蛋白转化酶枯草溶菌素9(PCSK9)与小而密低密度脂蛋白胆固醇(sd LDLC)的关系。方法收集2014年3月至2014年12月在山西医科大学第一医院住院且行冠状动脉造影术确诊为冠心病的患者100例作为冠心病组,同期健康体检者67例作为对照组。Lipoprint脂蛋白分析仪检测LDLC颗粒大小、sd LDLC颗粒数及sd LDLC所占LDLC的百分比(简称sd LDLC百分比);酶联免疫吸附法测定血清PCSK9。结果冠心病组LDLC颗粒大小低于对照组(264.07±6.78比267.37±5.15,P<0.01),sd LDLC颗粒数多于对照组(5.0±9.5比4.0±5.0,P<0.05),sd LDLC百分比大于对照组(5.95%±10.50%比3.70%±5.85%,P<0.01)。冠心病组血清PCSK9显著高于对照组(15.48μg/L比14.95μg/L,U=-2.74,P=0.006)。冠心病组血清PCSK9与sd LDLC百分比、LDLC呈正相关(r=0.212,P=0.034;r=0.202,P=0.032)。结论冠心病患者血清PCSK9与sd LDLC百分比呈正相关,抑制PCSK9可以预防冠心病。Aim To investigate the relationship between serum proprotein convertase subtilisin/kexin type 9 （PCSK9） and small and dense low density lipoprotein cholesterol （sdLDLC） in patients with coronary heart disease （CHD）. Methods From March 2014 to December 2014 in the first hospital of Shanxi Medical University, 100 patients with CHD diagnosed by coronary angiography were collected as CHD group, and 67 healthy subjects were served as control group. Lipoprint lipoprotein analyzer was used to measure the LDLC particle size, sdLDLC particle number and the percentage of sdLDLC in LDLC （sdLDLC percentage ）. Serum PCSK9 level was detected by enzyme-linked immunosorbent assay. Results Compared with the control group, LDLC particle size decreased （264.07 ± 6.78 vs. 267.37±5.15, P〈0.01）, sdLDLC particle number increased （5.0±9.5 vs. 4.0±5.0, P〈0.05）, sdLDLC percentage increased （5.95%±10.50% vs. 3.70%±5.85%, P〈0.01） in the CHD group. The serum PCSK9 level in CHD group was significantly higher than that in control group （ 15.48 μg/L vs. 14.95 txg/L, U=-2.74, P=0.006）. In the CHD group, serum PCSK9 level was positively correlated with sdLDLC percentage and LDLC （ r = 0.212, P = 0.034; r = 0.202, P = 0. 032）. Conclusion Serum PCSK9 level is positively correlated with sdLDLC percentage in patients with CHD, and the inhibition of PCSK9 can prevent CHD.

关 键 词：冠心病 前蛋白转化酶枯草溶菌素9 小而密低密度脂蛋白胆固醇 

分 类 号：R541.4[医药卫生—心血管疾病]